Showing results (931-940 of 2,823) with videos related to

Sort By:
Pageof 283
Cytotherapy|April 18, 2008
Data management in the cell therapy production facility: the batch process record (BPR)We Janssen
Cytotherapy|April 18, 2008
Alloreactivity of ex vivo-expanded T cells is correlated with expansion and CD4/CD8 ratioP Mercier-Letondal, N Montcuquet, D Sauce, et al.
Cytotherapy|April 2, 2019
Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cellsJay G Tanna, Robert Ulrey, Kirsten M Williams, et al.
Cytotherapy|August 30, 2019
Clinical effect and safety of dendritic cell-cytokine-induced killer cell immunotherapy for pancreatic cancer: a systematic review and meta-analysisYa-Li Liu, Lu-Xi Yang, Fan Zhang, et al.
Cytotherapy|May 11, 2015
International Society for Cell Therapy Facility Sanitization Survey Laboratory Practices Committee ReportVarda Deutsch, Andrew Havens, Karen Snow
Cytotherapy|May 13, 2015
Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignanciesZhen Zhang, Liping Wang, Zhenzhen Luo, et al.
Cytotherapy|September 1, 2025
Fast tumor-infiltrating lymphocytes (TILs): rapid manufacture of an adoptive cellular therapeutic from pleural infiltrating T cells for intrapleural administrationVera S Donnenberg, John Lister, Charlene L Briedenbaugh, et al.
Cytotherapy|August 8, 2016
A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapyAbdullah Alsuliman, Stanley H Appel, David R Beers, et al.
Cytotherapy|August 8, 2016
Expanded and armed natural killer cells for cancer treatmentNoriko Shimasaki, Elaine Coustan-Smith, Takahiro Kamiya, et al.
Cytotherapy|July 18, 2016
Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patientsIsabelle Müller, Dominik Altherr, Matthias Eyrich, et al.
Pageof 283